Important note: Information in this article was accurate in July 2002. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; July 22, 2002
Michael Greer, Senior Medical Writer
Dr. Christopher G. Lange and colleagues at Case Western Reserve University in Cleveland, Ohio, the University Hospitals of Cleveland, and the Salvador Zubiran National Institute of Nutrition and the National Institute of Respiratory Illness in Mexico City assessed immune function in patients who acheived viral suppression with highly active antiretroviral therapy (HAART).
Even though CD4 cell counts improved during HAART, immune responses to antigen challenge were not significantly greater than those seen in untreated patients, Lange and coauthors found.
Median CD4 cell counts more than tripled as viral loads dropped during HAART, to 483 cells/µL from nadirs of 150 cells/µL, study data showed. However, untreated patients demonstrated significantly higher levels of activated CD4 and CD8 cells.
Moreover, lymphocyte proliferation (LP) and delayed type hypersensitivity (DTH) responses to most antigens were similar in HAART-treated and -naive patients, the researchers said. One exception was HIV Gag antigen, which provoked significantly greater LP responses in HAART-treated patients.
DTH responses to mumps antigens were also augmented during HAART (Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection, J Acquir Immune Defic Syndr 2002 May 1;30(1):33-40.
"Thus, HIV-1-infected patients who experienced substantial increases in CD4+ T-lymphocyte counts after suppression of viral replication on HAART had fewer activated lymphocytes and similar immune function when compared with findings in untreated patients with similar CD4+ T-cell counts," Lange and colleagues concluded.
The corresponding author for this report is Michael M. Lederman, University Hospitals of Cleveland, Dept. of Medicine, Division of Infectious Diseases, 2061 Cornell Room 301 C, Cleveland, OH 44106, USA.
Key points reported in this study include:
This article was prepared by AIDS Weekly editors from staff and other reports.
020722
AW020711
Copyright © 2002 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.